Skip to Main Content

National Coverage Analysis (NCA) Tracking Sheet for Screening Immunoassay Fecal-Occult Blood Test (CAG-00180N)

CMS covers colorectal cancer screening using fecal-occult blood testing (FOBT), sigmoidoscopy, colonoscopy and barium enema (42 CFR 410.37).  On July 11, 2002, the Centers for Medicare  & Medicaid Services (CMS) received a formal request from Enterix, Inc. and a number of physicians, asking that we initiate a national coverage determination (NCD) on the use of its screening immunoassay fecal-occult blood test kit, Insure®, that includes the use of a special brush for the collection of stool samples.  However, we were unable to accept that request since 42 CFR 410.37(a)(2) defined FOBT as a guaiac-based test only.  On December 31, 2002, CMS published the 2003 Physician Fee Schedule final rule (CMS-1204-FC), which included a provision that amends section 410.37(a)(2) allowing CMS to use the NCD process to determine coverage of other types of FOBTs.  This rule change has an effective date of March 1, 2003.  Therefore, we have accepted the Enterix, et. al. request that we include coverage of its screening immunoassay FOBT product under the Medicare screening FOBT benefit.  However, our formal evaluation of this issue will not begin until the effective date of the rule change.  We will accept public comments on this issue until that time.

Colorectal Cancer Screening Tests
Requestor Name(s)Mr. Robert C. Bruce, Vice President and Chief Operating Officer, Enterix Inc.; James E. Allison, M.D.; Bernard Levin, M.D.; Anthony R. Mattia, M.D.; Ronald E. Myers, Ph.D.; Sidney J. Winawer, M.D.
Formal Request Accepted and Review Initiated03/01/2003
Expected NCA Completion Date10/24/2003
Public Comment Period03/01/2003 - N/A
Decision Memo Released11/04/2003
Lead Analyst(s)
  • William Larson
Lead Medical Officer(s)
  • Joseph Chin, M.D.
  • Lawrence Schott, M.D., M.S.

January 17, 2003

Request for consideration of Enterix’s immunoassay FOBT product accepted by Coverage and Analysis Group.  Our formal evaluation of this issue will begin after the effective date of the 2003 Physician Fee Schedule Final Rule.  The expected dates entered above will be corrected if necessary at that time.

March 3, 2003

The CMS 2003 Physician Fee Schedule final rule (CMS-1204-FC) is now effective and the formal evaluation of this NCD has begun.   We have referred this issue to the Agency for Healthcare Research & Quality for a technology assessment, which will also include a cost effectiveness analysis for use of this test as a screening test.  We will continue to accept public comments.

August 26, 2003

CMS has received the technology assessment from AHRQ. It can be found at http://www.cms.hhs.gov/coverage/download/id87.zip. New due date will be in 60 days.

November 4, 2003

85